Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

42180 reported adverse events

Drugs of this class: EFAVIRENZ NEVIRAPINE EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE ETRAVIRINE DORAVIRINE DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE

These side effects are most commonly reported by patients taking drugs of the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class:

#	Side effect	Count
0	BONE DENSITY DECREASED	7421
1	CHRONIC KIDNEY DISEASE	4446
2	RENAL INJURY	3982
3	TOOTH LOSS	3799
4	PAIN	3726
5	RENAL FAILURE	3611
6	EMOTIONAL DISTRESS	3535
7	SKELETAL INJURY	3534
8	OSTEONECROSIS	3472
9	BONE LOSS	3431

See all common reactions for Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Drugs of the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA	86	0.8113
1	CONGENITAL NEOPLASM	19	0.7917
2	HEPATIC DISPLACEMENT	17	0.7727
3	HUMAN IMMUNODEFICIENCY VIRUS TRANSMISSION	143	0.6976
4	DIAPHRAGMATIC APLASIA	18	0.6923
5	PINEALOBLASTOMA	49	0.5444
6	HIV-ASSOCIATED NEUROCOGNITIVE DISORDER	36	0.5000
7	CLOACAL EXSTROPHY	26	0.4906
8	TOOTH INJURY	1474	0.4857
9	BLADDER AGENESIS	31	0.4844

See all enriched reactions for Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]